| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 10, 2026 | Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8® | ReActiv8® Restorative NeurostimulationTM demonstrated statistically significant and clinically meaningful superiority vs. standard of care in all primary and secondary measures of disability, pain and quality of life
Safety profile consiste... |
| Jul 1, 2026 | Protagonist Therapeutics Reports Granting of Inducement Awards | NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment... |
| Jan 27, 2026 | Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer | SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (S... |
| Jan 6, 2026 | Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference | SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of in... |
| Dec 22, 2025 | Kazia Therapeutics Regains Full Nasdaq Listing Compliance | Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength
SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA... |
| Dec 11, 2025 | NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO | Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer ca... |
| Dec 10, 2025 | Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+ | First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters
Reinvigoration of immune system + turning cold tumors hot
Preliminary ex-vivo data in HER2+ pa... |
| Dec 4, 2025 | NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO | Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance
The Phase 1 ragistomig study achieved... |
| Dec 2, 2025 | Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities | SYDNEY, Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional an... |
| Nov 21, 2025 | NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward | Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program
The ability to attract seasoned ophthalmolo... |
| Nov 19, 2025 | Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy | SYDNEY, Nov. 19, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized... |
| Oct 29, 2025 | I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform | New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide
Strategy centers on broadening access to global capital and innovation through a planned H... |
| Oct 27, 2025 | Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner | SYDNEY, Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) ... |
| Oct 17, 2025 | I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences | New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide
Intention to pursue a H... |
| Oct 16, 2025 | Clarity signs copper-67 Supply Agreement with Nusano | SYDNEY, Oct. 16, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment ou... |
| Oct 7, 2025 | Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program | SYDNEY, Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the "Agreement") with QIMR Bergho... |
| Sep 11, 2025 | Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy | SYDNEY, Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer.... |
| Aug 1, 2025 | Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market | SYDNEY, Aug. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional in... |
| Jul 9, 2025 | Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial | SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and sta... |
| Jun 10, 2025 | Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease | London, UK – 10 June, 2025 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces that AstraZeneca has selected a lead T... |
| May 7, 2025 | Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update | - End-of-Phase 2 meeting with FDA requested for Alzheimer’s disease -
- Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC -
- Two posters at ARVO describe zervimesine's role supporting retinal cell health -... |
| May 7, 2025 | Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update | — Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million
— Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million
— Conference call scheduled for today at 4:30 pm ET
WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE)... |
| Apr 23, 2025 | Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025 | WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services a... |
| Apr 17, 2025 | Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano | Highlights
Clarity has signed a commercial-scale agreement with Nusano, Inc. ("Nusano") for supply of copper-64 (Cu-64 or 64Cu) isotope.
The 190,000 square foot Nusano facility in West Valley City, Utah is capable of producing mor... |
| Apr 1, 2025 | Clene to Present at the Jones Healthcare and Technology Innovation Conference | SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolut... |
| Apr 1, 2025 | Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes | PURCHASE, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented biomarker results fr... |
| Mar 24, 2025 | Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights | Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALS
Clene planning to initiate the confirmatory Phase 3 RESTORE-ALS trial in subjects with ALS in mid-2025
Se... |
| Mar 24, 2025 | Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results | FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval
FDA recommended measuring skin FXN ... |
| Mar 20, 2025 | Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update | Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB)
Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer’s Disease Subgroup
2025 Objective:... |
| Mar 19, 2025 | MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers
Expanded strategic research collaborations with industry leaders, now including Kerecis
$20 million in revenue for 2024; $24 million projected for 2025; $4... |
| Mar 13, 2025 | Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social | Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers
PARIS, 13 mars 2025 (GLOBE NEWSWIRE) --
Paris, France, le 13 mars 2025
Place de cotation : Euronext Paris / Nasdaq
... |
| Mar 13, 2025 | Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results | Conference Call and Live Audio Webcast Scheduled for March 20, 2025
PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegen... |
| Mar 13, 2025 | Voting Rights and Shares Capital of the Company | In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, March 13, 2025 (GLOBE NEWSWIRE) --
Paris, France, M... |
| Mar 13, 2025 | Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results | PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release ... |
| Mar 13, 2025 | Voting Rights and Shares Capital of the Company | In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, March 13, 2025 (GLOBE NEWSWIRE) --
Paris, France, M... |
| Mar 12, 2025 | Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment | New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage
SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopha... |
| Mar 12, 2025 | Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing | PURCHASE N.Y., March 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), was notified by th... |
| Mar 7, 2025 | Nusano’s Jzaneen Lalani Named to Top 50 Women Leaders in Healthcare Technology List | WEST VALLEY CITY, Utah, March 07, 2025 (GLOBE NEWSWIRE) -- The Healthcare Technology Report has named Jzaneen Lalani to its Top 50 Women Leaders in Healthcare Technology of 2024 list. Lalani is the Chief Business Officer (CBO) of Nusano, a ... |
| Mar 7, 2025 | Nusano’s Jzaneen Lalani Named to Top 50 Women Leaders in Healthcare Technology List | WEST VALLEY CITY, Utah, March 07, 2025 (GLOBE NEWSWIRE) -- The Healthcare Technology Report has named Jzaneen Lalani to its Top 50 Women Leaders in Healthcare Technology of 2024 list. Lalani is the Chief Business Officer (CBO) of Nusano, a ... |
| Mar 6, 2025 | Clene to Present at the 37TH Annual Roth Conference | SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revoluti... |
| Mar 6, 2025 | Clene to Present at the 37TH Annual Roth Conference | SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revoluti... |
| Mar 3, 2025 | Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025 | BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), ”), a clinical-stage biotechnology developing impactful treatments for neuropsychiatric disorders, bringing new hope an... |
| Mar 3, 2025 | MediWound to Report Fourth Quarter and Full Year 2024 Financial Results | YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the fourth quarter ... |
| Mar 3, 2025 | Opthea Announces Phase 2b Wet AMD Publication | Baseline angiographic lesion characteristics predictive of clinical response
Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina
MELBOURNE, Australia and PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Opthe... |
| Feb 27, 2025 | Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD | PURCHASE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates, (the “Company” or “Cognition”) announced the publication of a manuscrip... |
| Feb 21, 2025 | Nusano Named “Researcher of the Year” at Inaugural Best of BioHive Awards | WEST VALLEY CITY, Utah, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company committed to bringing supply stability and innovation to radioisotope markets, was named “Researcher of the Year” at the inaugural Best of BioHive Awards on... |
| Feb 12, 2025 | Voting Rights and Shares Capital of the Company | In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Feb. 12, 2025 (GLOBE NEWSWIRE) --
Paris, France, Fe... |
| Feb 12, 2025 | MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers | Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure
Interim analysis planned after 65% of patients complete treatment, expected in mid-2026
Strategic research collaboration... |
| Feb 7, 2025 | Opthea to Present at Oppenheimer Healthcare Conference | MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre... |
| Feb 7, 2025 | Nusano to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference | WEST VALLEY CITY, Utah, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, today announced the company’s CFO Pushkar Bedekar will present at Oppenheimer’s 35th Annual Healthcare Life Sc... |
| Feb 6, 2025 | Opthea Wet AMD Data Featured at Macula Society Meeting | MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progr... |
| Jan 30, 2025 | Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC | – Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB –
– Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI A-L),... |
| Jan 30, 2025 | Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC | – Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB –
– Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI A-L),... |
| Jan 28, 2025 | Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC | - PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)
- Commercial capabilities build out in process, with proposed launch in PSVT targeted for mid-2025
- Plans to initiate ... |
| Jan 16, 2025 | Nusano and Atley Solutions in Collaboration to Accelerate Astatine-211 Development | VALENCIA, Calif. and GOTHENBURG, Sweden, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, and Atley Solutions, a global leader in commercial products and services for astatine-related... |
| Jan 16, 2025 | Nusano and Atley Solutions in Collaboration to Accelerate Astatine-211 Development | Nusano isotope production to deliver breakthrough, 100X increase in global At-211 supply, and Atley’s radiopharmaceutical manufacturing technology to enable scalable At-211 radiopharmaceutical supply
VALENCIA, Calif. and GOTHENBURG, Sweden,... |
| Jan 10, 2025 | Nusano Announces Isotope Availability | VALENCIA, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Nusano, a privately held physics company transforming the production of radioisotopes utilized in radiopharmaceuticals, clean energy and aerospace, today announced the initial isotope avai... |
| Jan 8, 2025 | Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences | PURCHASE, N.Y., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that CEO Lisa Ricciar... |
| Jan 8, 2025 | Opthea to Host Investor Days in New York and Australia | Updates on commercial insights and readiness plans for sozinibercept in wet AMD
Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET
In-person events in Sydney on February 3 and Melbourne on February 5
MELBOURN... |
| Dec 23, 2024 | Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq | BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangement in relation to Bionomics Limited’s pro... |
| Dec 23, 2024 | Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq | BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangement in relation to Bionomics Limited’s pro... |
| Dec 19, 2024 | Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan | Secures new $10.0 million debt facility to replace remaining $7.85 million of Avenue Capital debt
Improves cash position enabling Clene to generate the additional data to support the new drug application of CNM-Au8® for ALS via an accelerat... |
| Dec 19, 2024 | Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference | Business update to include masked Phase 3 patient demographics and baseline characteristics
Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California
MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE ... |
| Dec 18, 2024 | Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies | - Improvements Across Measures of Behavior, Function, Cognition and Movement -
- Expediting Plans to Advance CT1812 into Late-Stage Trials -
- Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) -
- Cognition... |
| Dec 16, 2024 | Bionomics Announces Supreme Court of New South Wales Approves Bionomics’ Re-Domiciliation | ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales, Australia (“Court”) has today made orders... |
| Dec 12, 2024 | Results of Scheme Meeting | ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is pleased to provide the following update on the status of its proposed re-domiciliation from Austr... |
| Dec 11, 2024 | Nusano to Host Virtual KOL Panel Discussion on December 17, 2024 Previewing the Year Ahead in Radioligand Therapy (RLT) | VALENCIA, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, today announced it will host a virtual key opinion leader (KOL) panel discussion on Tuesday, December 17, 2024 at 1:... |
| Dec 11, 2024 | Voting Rights and Shares Capital of the Company | In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Dec. 11, 2024 (GLOBE NEWSWIRE) --
Paris, France, De... |
| Dec 10, 2024 | FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS | FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial to support earlier presented findings
FDA recommends a follow-up meeting to discu... |
| Dec 3, 2024 | Nusano Names Medical Radioisotopes Advisory Board | VALENCIA, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, today announced the creation of a Medical Radioisotopes Advisory Board. This panel of internationally recognized lea... |
| Dec 3, 2024 | Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024 | FARMINGTON HILLS, Mich., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophth... |
| Nov 26, 2024 | MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update | EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025
FDA Approves NexoBrid for Pediatric Use
$25 Million Financing and €16.25 Million EIC Funding Strengthen Cash Runway to Profita... |
| Nov 20, 2024 | Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024 | WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and... |
| Nov 20, 2024 | Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024 | WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and... |
| Nov 13, 2024 | Voting Rights and Shares Capital of the Company | In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Nov. 13, 2024 (GLOBE NEWSWIRE) --
Paris, France, No... |
| Nov 13, 2024 | Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update | - CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD -
- On track to report topline results from Phase 2 SHIMMER... |
| Nov 13, 2024 | Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights | Clene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024, in a Type C meeting to discuss the potential for an accelerated approval pathway in ALS and are awaiting meeting minutes
Cash, cash equivalents and marketable s... |
| Nov 12, 2024 | NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms | Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submissionAdded expert industry leaders to Supervisory Board, further strengthening support f... |
| Nov 12, 2024 | NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms | Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submission Added expert industry leaders to Supervisory Board, further strengthening support ... |
| Nov 12, 2024 | Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | FARMINGTON HILLS, Mich., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies ... |
| Nov 12, 2024 | Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update | In October, Ocuphire Pharma acquired Opus Genetics, creating a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal diseases (IRDs)
The pro forma cash balance of the combined compa... |
| Nov 12, 2024 | Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | FARMINGTON HILLS, Mich., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies ... |
| Nov 12, 2024 | Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum | PURCHASE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that President and CE... |
| Nov 12, 2024 | Nusano to Present at William Blair Virtual Radiopharmaceuticals Event | VALENCIA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, today announced the company’s CEO Chris Lowe will present at William Blair’s Innovators Series: Radiopharmaceuticals... |
| Nov 12, 2024 | Nusano to Present at William Blair Virtual Radiopharmaceuticals Event | VALENCIA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, today announced the company’s CEO Chris Lowe will present at William Blair’s Innovators Series: Radiopharmaceuticals... |
| Nov 12, 2024 | MediWound to Report Third Quarter 2024 Financial Results | YAVNE, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ... |
| Nov 8, 2024 | Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement | ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators ... |
| Nov 8, 2024 | Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement | ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators ... |
| Nov 7, 2024 | Bionomics to Present at the 2024 CNS Summit | ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators ... |
| Nov 4, 2024 | Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program | ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators ... |
| Nov 1, 2024 | Galecto Reports Third Quarter 2024 Financial Results | - Completed strategic review to focus on oncology and severe liver diseases
- Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines
- Appointed Dr. ... |
| Nov 1, 2024 | Galecto Reports Third Quarter 2024 Financial Results | - Completed strategic review to focus on oncology and severe liver diseases
- Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines
- Appointed Dr. ... |
| Oct 31, 2024 | NANOBIOTIX to Participate in Multiple Investor Conferences in November | ~ Guggenheim’s Inaugural Healthcare Innovation Conference, Nov 11-13 ~
~ Stifel Healthcare Conference, Nov 18-19 ~
~ Jefferies London Healthcare Conference, Nov 19-21 ~
PARIS and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTI... |
| Oct 31, 2024 | Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD | - Patient characteristics are consistent with other DLB studies -
PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that ... |
| Oct 29, 2024 | Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD | - Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer’s disease pathology -
- ADAS-Cog 11 scores showed 95% slowing of decline -
- MMSE scores showe... |
| Oct 22, 2024 | BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement | CARSON CITY, Nev., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and... |
| Oct 22, 2024 | Ocuphire Pharma Announces Acquisition of Opus Genetics | Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations
New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early ons... |
| Oct 22, 2024 | BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement | CARSON CITY, Nev., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and... |
| Oct 22, 2024 | Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB) | PURCHASE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has released a new Conversations... |
